Colorado has recently become the first state to explicitly safeguard neural data privacy, enacting a law on Wednesday, April 17th, 2024. Essentially, this legislation acknowledges that data generated by the nervous system is sensitive.
Supporters in Colorado expressed concerns that without proper safeguards, new devices might enable malicious actors to manipulate an individual's thoughts. Lawmakers in California and Minnesota are similarly evaluating protections for neural data.
Modern healthcare and medical research heavily rely on technology and data. As new technologies emerge, they bring expanded challenges for privacy. The recent move by Colorado demonstrates that regulatory frameworks must remain adaptable and flexible, evolving to cover new scenarios that might not have been envisioned just a few years ago. This is particularly relevant for neurodata and neurotechnology.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
FTC Completes Updates to Health Breach Notification Rule for Health Apps
The Federal Trade Commission announced it has finalized changes to the Health Breach Notification Rule (HBNR) that will strengthen and modernize the rule by clarifying its applicability to health apps and other similar technologies and expanding the information that covered entities must provide to consumers when notifying them of a breach of their health data.
The European Health Data Space overcomes its final obstacle in Parliament
iliomad is deligthed to have supported the ICM - Institut du Cancer de Montpellier in their CNIL's authorization process
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study. The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022. The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer. We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
